EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

INVESTIGATION OF NEUROPROTECTIVE EFFECT OF RASAGILINE IN DIABETIC NEUROPATHY IN STREPTOZOTOCIN INDUCED TYPE 2 DIABETIC RATS

Amit Kumar Gangwar*

ABSTRACT

Background One of the most common complications of diabetes is the involvement of the peripheral and autonomic nervous systems . An important risk factor for the development of diabetic neuropathy in patients with type 1 or type 2 diabetes is the duration and severity of hyperglycaemia. Diabetic neuropathy is ―the presence of symptoms and/or signs of peripheral nerve dysfunction in persons with diabetes after the exclusion of other causes.‖ Till date there is no effective treatment available for diabetic neuropathy, However, it can be managed using certain pharmacological and, non-pharmacological treatments. The aim of this study is to investigate the neuroprotective effect of rasagiline in diabetic neuropathy. Methods: Diabetes was induced by a single dose of STZ (60 mg/kg i.p). After the administration of Streptozotocin the animals showed marked hyperglycaemia, reduction in body weight and other signs of neuropathy like thermal allodynia (hot and cold), thermal hyperalgesia and motor co-ordination was compared to the animals of the control group. Results : After 28 days of treatment with Rasagiline ( 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg) in combination with Glimepiride ( 10 mg/kg), rats showed significant reduction in serum glucose level, and improvement in body weight. Rasagiline combined with Glimepiride showed good results in different parameters such as thermal allodynia (hot and cold), thermal hyperalgesia and motor co-ordination in comparison with diabetic control group. The most significant effect was seen with 1.0 mg/kg of rasagiline in combination with Glimepiride (10 mg/kg) after 28th day of treatment. Conclusion: Rasagiline can, therefore, be concluded to be effective treatment option for diabetic complications like neuropathy. This is due to its inhibitory effect on MAO-B.

Keywords: thermal hyperalgesia, thermal allodynia, cold allodynia and motor inco-ordination.

[Full Text Article] [Download Certificate]